MONOPRIL
LOE ApproachingNDAORALTABLET
Approved
May 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONOPRIL is an oral small-molecule tablet approved by the FDA in 1991 as an NDA product from Bristol Myers Squibb. The specific indication and mechanism of action are not documented in available data, limiting detailed clinical characterization.
LOE Approaching
Product is approaching loss of exclusivity, indicating a contracted commercial team focused on maximizing remaining branded revenues and transitioning to post-LOE defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero currently linked job openings reflect the LOE-approaching lifecycle stage and likely workforce optimization. Career opportunities on this product are limited and focused on managed decline, retention of remaining market share, and preparation for generic competition.
Brand ManagerProduct Manager
Worked on MONOPRIL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.